Relmada Therapeutics, Inc. (RLMD)

Relmada Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1.35	3.86	4.09	5.4	44.44	2.5
Short-Term Investments	19.27	41.05	92.23	142.93	167.47	114.6
Cash & Short-Term Investments	20.62	44.91	96.32	148.32	211.91	117.09
Cash Growth	-70.73%	-53.38%	-35.06%	-30.01%	80.98%	0.56%
Other Receivables	-	-	-	0.51	0.09	0.08
Total Trade Receivables	-	-	-	0.51	0.09	0.08
Other Current Assets	0.47	0.89	1.19	4.04	11.3	0.9
Total Current Assets	21.09	45.8	97.51	152.87	223.3	118.07
Net Property, Plant & Equipment	-	-	-	-	-	0
Other Long-Term Assets	0.02	0.02	0.04	0.03	0.03	0.11
Total Assets	21.12	45.82	97.55	152.91	223.33	118.19
Accounts Payable	1.36	4.13	3.51	5.26	11.19	8.35
Accrued Expenses	3.77	6.16	8.69	7.21	3.87	4.26
Total Current Liabilities	5.13	10.29	12.19	12.47	15.06	12.6
Other Long-Term Liabilities	0.03	0	-	-	-	-
Total Long-Term Liabilities	0.03	0	-	-	-	-
Total Liabilities	5.17	10.3	12.19	12.47	15.06	12.6
Common Stock	0.03	0.03	0.03	0.03	0.03	0.02
Additional Paid-in Capital	684.22	676.37	646.23	602.52	513.3	284.88
Retained Earnings	-668.31	-640.88	-560.9	-462.11	-305.07	-179.32
Shareholders' Equity	15.95	35.52	85.36	140.44	208.26	105.58
Total Liabilities & Equity	21.12	45.82	97.55	152.91	223.33	118.19
Net Cash (Debt)	20.62	44.91	96.32	148.32	211.91	117.09
Net Cash Growth	-54.09%	-53.38%	-35.06%	-30.01%	80.98%	0.65%
Net Cash Per Share	0.67	1.49	3.20	5.01	12.07	7.51
Book Value	15.95	35.52	85.36	140.44	208.26	105.58
Book Value Per Share	0.51	1.18	2.84	4.74	11.87	6.77
Tangible Book Value	15.95	35.52	85.36	140.44	208.26	105.58
Tangible Book Value Per Share	0.51	1.18	2.84	4.74	11.87	6.77

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q